Clone:
REA671
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1

Specifications for CD38 antibodies

Overview

Clone REA671 recognizes the human CD38 antigen, a single-chain type II transmembrane glycoprotein with enzymatic activity. It is present on the majority of hematopoietic cells, prevalent during early differentiation and activation processes. Terminally differentiated B cells (plasma cells) express CD38 brightly. Furthermore, CD38 is constitutively expressed in several tissues, for example, brain, muscle, and kidney. CD38, a disease marker for human leukemias and myelomas, plays a role in the pathogenesis and outcome of human immunodeficiency virus infection and chronic lymphocytic leukemia, and controls insulin release and also the development of diabetes. Furthermore, it catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD
+
to ADP-ribose which is essential for the regulation of intracellular Ca
2+
.
Additional information: Clone REA671 displays negligible binding to Fc receptors.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD38 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Detailed product information

Technical specifications

CloneREA671
Isotyperecombinant human IgG1
Type of antibodyRecombinant antibodies
Specieshuman
AntigenCD38
Molecular mass of antigen [kDa]34
Distribution of antigenB cells, plasma cells

Resources for CD38 antibodies

Certificates

Please follow this
link
to download the Certificate of Conformity (CoC) by lot number.

References for CD38 antibodies

Publications

  1. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  2. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  3. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  4. Yoon-Sang, K. et al. (2010) Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol. Ther. 18(7): 1310-1317
  5. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  6. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  7. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22

Seems like you are coming from USA!
Do you want to visit our website in your country?